Delcath Systems (NASDAQ:DCTH) Sees Unusually-High Trading Volume on Analyst Upgrade

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) saw strong trading volume on Wednesday after HC Wainwright raised their price target on the stock from $32.00 to $36.00. HC Wainwright currently has a buy rating on the stock. Approximately 569,519 shares changed hands during mid-day trading, an increase of 19% from the average daily volume of 477,218 shares. The stock last traded at $21.8080 and had previously closed at $20.10.

A number of other equities research analysts have also recently commented on the company. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Weiss Ratings downgraded Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Finally, BTIG Research boosted their price objective on Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $29.33.

Key Stories Impacting Delcath Systems

Here are a few of the latest stories about DCTH:

• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its price target from $32 to $36. It also increased its FY2028–FY2030 EPS estimates, signaling stronger longer-term earnings expectations. HC Wainwright rating
• Positive Sentiment: Following the strong earnings news, DCTH reached a new 12-month high. Report on Delcath’s 12-month high
• Negative Sentiment: HC Wainwright trimmed its Q2 2027 EPS estimate slightly, to $0.11 from $0.12, a modest offset to its improved longer-term forecasts.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Delcath Systems during the 2nd quarter valued at about $48,000. IFP Advisors Inc purchased a new stake in Delcath Systems in the second quarter worth about $52,000. Royal Bank of Canada boosted its position in Delcath Systems by 14.8% during the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after acquiring an additional 2,364 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Delcath Systems during the 1st quarter valued at approximately $306,000. Finally, Sei Investments Co. boosted its position in Delcath Systems by 100.0% during the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock valued at $409,000 after acquiring an additional 22,029 shares in the last quarter. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Up 8.0%

The business has a fifty day simple moving average of $15.60 and a two-hundred day simple moving average of $12.54. The stock has a market cap of $753.16 million, a PE ratio of 135.66 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a return on equity of 5.78% and a net margin of 6.05%. The firm had revenue of $35.10 million for the quarter, compared to the consensus estimate of $25.99 million. On average, research analysts predict that Delcath Systems, Inc. will post -0.17 earnings per share for the current year.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.